Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Camp4 Therapeutics (CAMP) over the last 3 years, with Q3 2025 value amounting to $75.3 million.

  • Camp4 Therapeutics' Cash & Equivalents rose 287863.92% to $75.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.3 million, marking a year-over-year increase of 287863.92%. This contributed to the annual value of $64.0 million for FY2024, which is 6685.51% up from last year.
  • As of Q3 2025, Camp4 Therapeutics' Cash & Equivalents stood at $75.3 million, which was up 287863.92% from $39.1 million recorded in Q2 2025.
  • Camp4 Therapeutics' Cash & Equivalents' 5-year high stood at $75.3 million during Q3 2025, with a 5-year trough of $2.5 million in Q3 2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $49.3 million (2025), whereas its average is $45.6 million.
  • As far as peak fluctuations go, Camp4 Therapeutics' Cash & Equivalents tumbled by 9499.1% in 2024, and later skyrocketed by 287863.92% in 2025.
  • Over the past 3 years, Camp4 Therapeutics' Cash & Equivalents (Quarter) stood at $38.4 million in 2023, then surged by 66.86% to $64.0 million in 2024, then grew by 17.58% to $75.3 million in 2025.
  • Its last three reported values are $75.3 million in Q3 2025, $39.1 million for Q2 2025, and $49.3 million during Q1 2025.